Essential Hypertension Clinical Trial
Official title:
The Effect of Aromatherapy Through Inhalation and Foot Massage on Blood Pressure and Stress Response in Individuals With Essential Hypertension
Objective: To investigate the effect of aromatherapy on blood pressure and stress response by
inhalation and foot massage in individuals with essential hypertension.
Methods: The randomized controlled trial is performed with 69 individuals diagnosed with
essential hypertension hospitalized. There are two interventions (group 1:
aromatherapy-inhalation method, group 2: aromatherapy-foot massage) and a control group in
the study. Blood pressure is measured with a digital sphygmomanometer after 10 minutes of
rest; stress response is determined by heart rate, blood cortisol levels and anxiety scale.
Aromatherapy with lavender oil is applied to the intervention groups; no application is made
to the control group and routine follow-up at the hospital continued.
Status | Recruiting |
Enrollment | 69 |
Est. completion date | August 3, 2020 |
Est. primary completion date | August 3, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - 18 years and over, - Have been diagnosed with essential hypertension for at least 6 months, - Blood pressure values are 120-180 mmHg for systolic pressure and 80-110 mmHg for diastolic pressure, - Receiving regular antihypertensive therapy, - No additional antihypertensive drug is added during the application, - Passing the odor sense test, - No current anxiolytic or hypnotic treatment, - Not diagnosed with psychiatric illness, - Not pre-applied, - Those who understand and speak Turkish, - No speech, hearing and vision loss, - Non-smoker, - Does not apply herbal treatment to lower blood pressure, - Individuals who agreed to participate in the research Exclusion Criteria: - An additional antihypertensive drug was added during the application, - Before each intervention, SKB = 180 or <120 mmHg and DKB = 110 or <80 mmHg, - Taking dialysis treatment, - In addition to its existing diseases, it is diagnosed with asthma, COPD and acute myocardial infarction. - With a known allergic response to lavender oil, - Applying herbal treatment to lower blood pressure, - Those who cannot pass the odor sense test, - Receiving current anxiolytic or hypnotic treatment, - Diagnosed with psychiatric illness, - Pre-implemented, - Who cannot understand and speak Turkish, - Speech, hearing and vision loss, - Smoker, - Individuals who do not agree to participate in the research |
Country | Name | City | State |
---|---|---|---|
Turkey | Bolu Elderly Health Center | Bolu |
Lead Sponsor | Collaborator |
---|---|
Abant Izzet Baysal University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean of blood pressure (mmHg) | In the study, a digital sphygmomanometer, which has been calibrated in comparison with the mercury sphygmomanometer, is used in order to prevent individual differences in the measurement of blood pressure. For accurate results, the sphygmomanometer sleeve is sized for adult individuals (width = about 20 cm, length = about 40 cm). In order for the blood pressure not to be affected by the conditions during the measurement, it is taken into account that the individual did not drink tea or coffee, take caffeine, and preferably did not eat during the 30 minutes prior to measurement. Measurements are made after the individual has been resting in a quiet room for at least 10 minutes. The measurements at the first interview are made from both arms, the blood pressure in the high arm is considered to be the blood pressure of the patient. Blood pressure measurements in the follow-ups are also made from this arm. | up to one week | |
Primary | Mean of heart rate (/dk) | The heart rate is the pressure of the left ventricle on the vascular wall of the blood that it throws into the aorta during systole from the skin surface.In the research, apical heart rate is measured with a stethoscope. | up to one week | |
Primary | Mean of blood cortisol level (mg/dl) | Adrenal cortisol release is largely regulated by the limbic system-hypothalamus-pituitary and adrenal (L-HPA) axis.When an individual detects an environmental stimulus or stress to be avoided, activation of the HPA-axis is initiated in the central nervous system, and a physiological process occurs to stimulate the adrenal gland to release glucocorticoids for cortisol release.There are sources showing that the maximum cortisol values are between 04:00 and 08:00. The half-life of cortisol in circulation is 60 minutes, so the blood concentration changes rapidly. For this reason, interventions in the study are performed within hours when the serum cortisol level is highest and blood will be drawn for cortisol 5 minutes after the application. | up to one week | |
Primary | Means of subjective anxiety scores | Spielberger State-Trait Anxiety Inventory is used to measure subjective anxiety scores.The State Anxiety Inventory is a 4-point Likert-type scale consisting of 20 questions aimed at measuring how individuals are feeling right now.The Trait Anxiety Inventory is a 20-item scale that generally determines how the individual feels, regardless of the situation and circumstances in which the individual is present. | up to one week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03708601 -
Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)
|
||
Not yet recruiting |
NCT05503953 -
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
|
Phase 3 | |
Recruiting |
NCT05526703 -
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy
|
Phase 3 | |
Completed |
NCT06395194 -
Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension
|
Phase 3 | |
Not yet recruiting |
NCT06418074 -
Effects of Exogenous Ketosis on Renal Function, Renal Perfusion, and Sodium Excretory Capacity
|
N/A | |
Completed |
NCT02890173 -
Study of CS-3150 in Patients With Essential Hypertension
|
Phase 3 | |
Completed |
NCT02944734 -
Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension
|
Phase 2 | |
Withdrawn |
NCT02096939 -
Microvascular Function in Primary Aldosteronism
|
N/A | |
Recruiting |
NCT01956786 -
Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
|
Phase 2/Phase 3 | |
Completed |
NCT02553512 -
Helius in Hypertension-I: The UK Hypertension Registry
|
N/A | |
Completed |
NCT01198249 -
Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension
|
Phase 1 | |
Completed |
NCT01001572 -
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
|
Phase 3 | |
Recruiting |
NCT00380289 -
Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension
|
N/A | |
Completed |
NCT00139698 -
Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
|
Phase 3 | |
Completed |
NCT00288184 -
Uric Acid in Essential Hypertension in Children
|
Phase 2 | |
Completed |
NCT01289886 -
Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06041529 -
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension
|
Phase 4 | |
Completed |
NCT04470830 -
A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea
|
||
Completed |
NCT00758524 -
A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension
|
Phase 2 | |
Recruiting |
NCT05109013 -
Juvenile Essential Arterial Hypertension and Vascular Function
|